Ozempic (Semaglutide) for the treatment of obesity: advantages and disadvantages from an integrative analysis

Authors

DOI:

https://doi.org/10.33448/rsd-v11i11.33963

Keywords:

Ozempic; Semaglutide; Obesity; Pharmacology.

Abstract

Objective: To analyze the advantages and disadvantages of Ozempic for the treatment of obesity. Methods: Through an integrative analysis, it was possible to highlight different investigations in scientific articles. The article established inclusion criteria, such as keywords, publication language and being on one of the preselected platforms (Scielo, PubMed and RDU) and also established exclusion criteria, such as incomplete research, was the subject investigated and without methods and explicit methods. Results: The Ozempic (semaglutide) has good results in helping to lose weight in obese patients. Despite being developed for the treatment of patients with type 2 diabetes mellitus, the results for obesity were positive. Among the main results is weight loss, which is directly conditioned to the dosage of medication, as well as a better energy intake and a lower preference for fatty foods in the patients' choice. All these factors were considered advantages. Among the disadvantages of using the drug is the fact that it is new in the market, which limits scientific research. According to the authors, some researchers have already established a causal relationship between the use of semaglutide and thyroid cancer in rodents; this factor has not been proven in humans and is considered a disadvantage. Final considerations: The use of Ozempic presents interesting results for weight loss, however, although the long-term side effects of the use of this drug are not known, a factor that may pose a risk to patients who are using Ozempic for it. treatment of obesity.

References

Ades L., Kerbauy R (2002). Obesidade: Realidades e Indagações. Psicologia. USP 13 (1).

Anjos, L. A. (2006) Obesidade e saúde pública. Fiocruz.

Aroda V. R., et al (2018). Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab. 45(5), 409-418.

Botelho et al. (2011) O Método da Revisão Integrativa nos Estudos Organizacionais. Gestão e Sociedade 5(11), 121-136.

Bray, et al. (2018) The Science of Obesity Management: An Endocrine Society Scientific Statement. Endocrine reviews, 39(2), 79–132.

De Paulo, C. M. et al. (2021) O uso de agonista do receptor GLP-1, semaglutida, como terapia para emagrecimento em pacientes obesos. Brazilian Journal of Surgery and Clinical Research, 35(1) 54-59.

Ercole et al. (2014). Revisão integrativa versus revisão sistemática. Revista Mineira de Enfermagem. 18(1).

Faeh D, et al. (2011) A obesidade, mas não o excesso de peso, está associada a um maior risco de mortalidade. Eur J Epidemiol. 26: 647.

Flegal, K. M., et al. (1998). Overweight and obesity in the United States: Prevalence and trends, 1960-1994. International Journal of Obesity and Related Metabolic Disorders, 22, 39-47.

Gomes, H. K.B.; Trevisan, M. (2021) O uso do ozempic (semaglutida) como medicamento off label no tratamento da obesidade e como auxiliar na perda de peso. Revista Artigos Com. 29

Guzmán, J.C, & Revelo Enriquez, B. N. (2022). Análisis de costoutilidad de dulaglutida en comparación con semaglutida en el tratamiento de la diabetes mellitus tipo 2 en Colombia. [Trabajo de grado especialización]. Medellín, Colombia. Universidad de Antioquia.

O'Neil P. M. et al (2018) Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 25(392), 637-649.

Paccosi S., et al. (2020) Obesity Therapy: How and Why? Curr Med Chem, 27(2):174-186.

Pérez J. P. (2021) Profundizando En La Eficacia, Seguridad Y Eficiencia De Un Nuevo Antidiabético: La Semaglutida Subcutánea SESCAM 23(1).

Peter, R.; Bain, S. C. Safety of injectable semaglutide for type 2 diabetes. Expert Opinion on Drug Safety. 19(7), p.785-798.

Pinheiro A. R. O. et al (2004). Abordagem Epidemiológica da Obesidade. Revista Nutrição, Campinas, 17(4):523-533.

Phillips A., Clements J. N. J. (2022) Clinical review of subcutaneous semaglutide for obesity. Clin Pharm Ther. 47(2):184-193.

Smits, M. M.; Van, R. D. l. (2021) Safety of semaglutide. Frontiers in Endocrinology, 12.

Tarozo M, et al. (2020) Impacto das Consequências Psicossociais do Estigma do Peso no Tratamento da Obesidade: uma Revisão Integrativa da Literatura. Psicologia, Ciência e Profissão. 40.

Wanderley EN, Ferreira VA (2010). Obesidade: uma perspectiva plural. Ciência & Saúde Coletiva, 15(1), 185-194.

Wilding, J. et al. (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal Of Medicine, 389 (11), 989-1002

World Health Organization (1998). Obesity: Preventing and managing the global epidemic. Report of a WHO Consultation on Obesity. Geneva.

Published

04/09/2022

How to Cite

SABBÁ, H. B. O.; VIANA, C. A. S.; SILVA, C. B.; ALVES, D. R.; MIRANDA, J. L. F.; RODRUIGUES, M. C.; SANTOS, P. H. F. dos. Ozempic (Semaglutide) for the treatment of obesity: advantages and disadvantages from an integrative analysis. Research, Society and Development, [S. l.], v. 11, n. 11, p. e587111133963 , 2022. DOI: 10.33448/rsd-v11i11.33963. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/33963. Acesso em: 22 dec. 2024.

Issue

Section

Health Sciences